L-AcetylleucineAlternative Names: N-acetyl-L-leucine; V 0251
Latest Information Update: 22 Apr 2015
At a glance
- Originator Pierre Fabre
- Class Anxiolytics; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Vertigo
- Discontinued Dizziness
Most Recent Events
- 31 Dec 2007 Phase-II clinical trials in Dizziness in France (unspecified route)